ARTICLE | Clinical News
CStone to start Phase I of HDAC6 inhibitor
March 14, 2019 11:42 PM UTC
CStone said China’s National Medical Products Administration (NMPA) approved an IND for a dose-escalation Phase I trial of CS3003 to treat advanced solid tumors and relapsed or refractory multiple myeloma. The trial of the selective histone deacetylase 6 inhibitor will be conducted in China and Australia...
BCIQ Company Profiles
BCIQ Target Profiles